Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MESO vs CAPR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CAPR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

CAPR Overall Winner 6-Pillar Tally: MESO 2 – 3 CAPR (1 Tie) Matrix Metrics: MESO 5 – 5 CAPR

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). MESO carries a Unified Composite Score of 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While MESO currently prints a higher short-term Unified Composite Score (34.6/100 SELL vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -42.6% operating margin) and revenue trajectory (-7.9% vs. +390.7% YoY).
  • Defensive Composite Rating Caution: Although CAPR compares more favorably head-to-head, both MESO (34.6/100 SELL) and CAPR (28.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MESO vs CAPR
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
34.6 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $13.64 · SMA50: $14.22
CAPR NASDAQ Head-to-Head Winner
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.3 · SMA20: $7.79 · SMA50: $8.08

6-Pillar Scorecard Institutional Category Breakdown (MESO 2 – 3 CAPR)

Columns: Metric · MESO · CAPR
1. Valuation Multiples CAPR
Forward P/E N/M 78.7x
Trailing P/E N/M 78.7x
PEG Ratio N/M 0.38x
EV / Revenue 14.1x 57.8x
2. Growth & Scale MESO
Revenue Growth (YoY) +390.7% -7.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $120M $11M
Market Cap $1.7B $595.4M
3. Profitability & Quality CAPR
Gross Margin 80.0% N/A
Operating Margin -42.6% 0.0%
Net Profit Margin -47.8% 0.0%
Return on Equity (ROE) -9.9% -100.5%
4. Balance Sheet & Cash Flow MESO
Cash Generation (TTM) -$45M EBITDA -$146M
Cash Flow Margin -37.1% EBITDA Mgn N/A
Net Cash / Leverage $4.38 Book/Sh · -9.9% ROE $48M Net Debt (0.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 76.8% (37th %ile) 637.1% (89th %ile)
Put/Call OI Skew Thin ADR Chain 1.57x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MESO (5) vs CAPR (5)
Institutional Metric MESO CAPR Criterion Row Edge
Market Capitalization
Scale
$1.7B $595.4M Larger Scale MESO
Trailing P/E Ratio
Valuation
N/M 78.7x Lower Multiple CAPR
Forward P/E Ratio
Valuation
N/M 78.7x Lower Multiple CAPR
Revenue Growth (YoY)
Growth
+390.7% -7.9% Higher Growth MESO
Operating Margin (TTM)
Profitability
-42.6% 0.0% Higher Margin CAPR
Net Profit Margin
Profitability
-47.8% 0.0% Higher Margin CAPR
Return on Equity (ROE)
Capital Efficiency
-9.9% -100.5% Higher ROE MESO
52-Week Range Position
Momentum
6% ($12–$22) 15% ($3–$40) Stronger Trend CAPR
Beta / 30D Volatility
Risk Regime
1.18β · 78% Vol 1.52β · 152% Vol Lower Realized Risk MESO
Unified Institutional Score
Composite Signal
34.6 / 100 (SELL) 28.0 / 100 (SELL) Higher Composite MESO
Trailing 12M Revenue (USD)
Operating Scale
$120M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
80.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.1x EV/Rev 0.38x PEG · 57.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) -$146M ($48M Net Debt (0.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAPR +32.33 pp
MESO: -6.1% · CAPR: +26.23%
3M Horizon CAPR +44.82 pp
MESO: -25.19% · CAPR: +19.63%
6M Horizon MESO +53.77 pp
MESO: -16.81% · CAPR: -70.58%
1Y Horizon CAPR +63.21 pp
MESO: -16.42% · CAPR: +46.79%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MESO vs CAPR. Trailing 12-month operating profitability (MESO -42.6% vs CAPR 0.0%) and valuation multiples (MESO N/M vs CAPR 78.7x Forward P/E) are benchmarked directly in Pillar 4 below.

MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M
CAPR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-100.5% · 78.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MESO vs CAPR Key Questions & Quantitative Answers

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). MESO carries a Unified Composite Score of 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MESO currently prints a higher short-term Unified Composite Score (34.6/100 SELL vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -42.6% operating margin) and revenue trajectory (-7.9% vs. +390.7% YoY). Defensive Composite Rating Caution: Although CAPR compares more favorably head-to-head, both MESO (34.6/100 SELL) and CAPR (28.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MESO leads the Growth & Scale pillar: MESO posts +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MESO generates $120M in USD-normalized revenue versus $11M for CAPR. In operating R&D and SG&A reinvestment, MESO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.

CAPR screens cheaper on headline valuation multiples. MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MESO (-9.9% ROE) versus CAPR (-100.5% ROE) capital efficiency.

In options market volatility and institutional positioning, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.